2024-03-15 17:07:00 ET
Ginkgo Bioworks (NYSE: DNA) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF , it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments.
But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know.
When biopharma businesses need to manufacture a large quantity of a biological reagent or product of some kind, they often choose to outsource it. But in order to outsource the process properly, they have to define the steps the contractors need to do to fulfill the specification. And in the context of bioengineering tasks for biomanufacturing purposes, that can be a tall order as the processes and technologies used for laboratory-scale work tend to be very different from the processes used for mass production.
For further details see:
Is Ginkgo Bioworks Stock a Buy?